Want to see PFE full AI Analyst Report?
Top Page
Pfizer
(NYSE:PFE)
Select Model
Select Model
Rating:64Neutral
Price Target:
$28.00
â–²(1.60% Upside)
Action:Reiterated
Date:06/19/26
Overall score reflects improving fundamentals and a positive earnings-call outlook (reaffirmed guidance, strong ex‑COVID momentum, cost-savings and pipeline progress), supported by an attractive dividend yield. The rating is held back by only moderate financial statement strength (higher leverage and weaker cash conversion) and a largely neutral technical setup.
Positive Factors
Late-stage R&D success
Multiple positive Phase III readouts materially de‑risk the pipeline, increasing probability of new approvals and label expansions. Over the medium term this supports durable revenue potential, offsets LOE, and strengthens Pfizer’s long‑term product mix and commercial optionality.
Negative Factors
Elevated leverage
Higher leverage reduces balance sheet flexibility and increases financing risk over the medium term. With debt elevated versus pre‑2023 levels, Pfizer has less capacity for large opportunistic M&A or accelerated buybacks without improving cash conversion or reducing net debt, constraining capital allocation optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Late-stage R&D success
Multiple positive Phase III readouts materially de‑risk the pipeline, increasing probability of new approvals and label expansions. Over the medium term this supports durable revenue potential, offsets LOE, and strengthens Pfizer’s long‑term product mix and commercial optionality.
Read all positive factors
Pfizer Key Performance Indicators (KPIs)
Any
Revenue by Geography
Breaks down revenue across different regions, revealing where Pfizer is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Breaks down revenue across different regions, revealing where Pfizer is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Data provided by:
The Fly
The FlyPfizer (PFE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$136.10B
Dividend Yield6.65%
Average Volume (3M)37.45M
Price to Earnings (P/E)18.2
Beta (1Y)0.41
Revenue Growth1.36%
EPS Growth-5.39%
CountryUS
Employees81,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)1.31
Shares Outstanding5,699,444,300
10 Day Avg. Volume44,110,695
30 Day Avg. Volume37,449,309
Financial Highlights & Ratios
PEG Ratio-4.33
Price to Book (P/B)1.64
Price to Sales (P/S)2.26
P/FCF Ratio15.59
Enterprise Value/Market Cap1.55
Enterprise Value/Revenue3.32
Enterprise Value/Gross Profit4.79
Enterprise Value/Ebitda12.57
Forecast
1Y Price Target
$28.83Price Target Upside4.62% Upside
Rating ConsensusHold
Number of Analyst Covering22
EPS Forecast (FY)2.96
Revenue Forecast (FY)$61.72B
Pfizer Business Overview & Revenue Model
Company Description
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic a...
How the Company Makes Money
Pfizer makes money primarily by selling branded prescription pharmaceuticals and vaccines. Revenue is generated when Pfizer supplies products—manufactured internally or through third-party manufacturing partners—to wholesalers, retailers and pharm...
Pfizer Earnings Call Summary
Earnings Call Date:May 05, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 04, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational execution: a revenue and EPS beat, healthy underlying growth ex-COVID (~7%), substantial momentum from launched and acquired products (22% operational growth, $3.1B in Q1), multiple positive clinical readouts and meaningful strategic wins (Vyndamax settlement, favorable Belgian court ruling). Management balanced near-term challenges — LOE dynamics, COVID seasonality, higher accrued royalties and increased R&D spend — with clear actions to drive long-term growth (pipeline advancement, vaccine programs, manufacturing and cost-savings targets, BD capacity). Overall, positives around commercial performance, pipeline progress and legal/cash-flow clarity meaningfully outweigh the manageable near-term headwinds.Positive Updates
Revenue and EPS Beat in Q1 2026
Total revenues of $14.5 billion in Q1 2026, exceeding expectations and representing a 2% operational increase year-over-year. Reported diluted EPS was $0.47 and adjusted diluted EPS was $0.75, both above expectations.
Negative Updates
Loss of Near-Term Exclusivity (LOE) Headwinds
Management reiterated significant LOE pressures through 2028 and stated leverage may remain around current levels or slightly higher during the transition. While settlement extended exclusivity for Vyndamax and reduced LOE impact, LOEs remain a material multi‑billion-dollar headwind over the coming years (company referenced prior ~$17B now ~ $14–15B).
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue and EPS Beat in Q1 2026
Total revenues of $14.5 billion in Q1 2026, exceeding expectations and representing a 2% operational increase year-over-year. Reported diluted EPS was $0.47 and adjusted diluted EPS was $0.75, both above expectations.
Read all positive updates
Company Guidance
Pfizer reaffirmed 2026 guidance, targeting total revenues of $59.5–$62.5 billion and adjusted diluted EPS of $2.80–$3.00, with adjusted gross margins expected in the mid‑70s; that outlook is supported by a strong Q1 showing (revenues $14.5B, +2% operational; ex‑COVID ~+7% operational), Q1 reported EPS $0.47 and adjusted EPS $0.75, adjusted gross margin ~76% and adjusted operating margin 38%. Management emphasized ongoing cost discipline and productivity targets—$7.2B of total net savings by end‑2026 (Phase I savings ~$700M this year, ~$175M realized in Q1)—while noting Q1 metrics such as launch/acquired product revenue $3.1B (+22% op), adjusted Opex $5.5B, operating cash flow $2.6B, leverage ~2.8x, $2.5B invested in R&D, $2.4B returned via dividends, BD capacity of ~ $7B (including ~$1.65B ViiV proceeds) and a $2.6B final TCJA payment; they also flagged assumptions that Paxlovid demand will remain low near term and most Comirnaty sales will be back‑half seasonal, and reiterated a long‑term view of entering a high single‑digit 5‑year revenue CAGR starting in 2029.Pfizer Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
62
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 63.31B | 62.58B | 63.63B | 59.55B | 100.33B | 81.29B |
| Gross Profit | 43.91B | 44.01B | 41.85B | 30.34B | 62.09B | 46.88B |
| EBITDA | 16.75B | 15.10B | 18.13B | 9.56B | 41.03B | 30.79B |
| Net Income | 7.49B | 7.77B | 8.02B | 2.13B | 31.36B | 22.15B |
Balance Sheet | ||||||
| Total Assets | 207.62B | 208.16B | 213.40B | 226.50B | 197.21B | 181.48B |
| Cash, Cash Equivalents and Short-Term Investments | 13.07B | 13.60B | 20.48B | 12.69B | 22.73B | 31.07B |
| Total Debt | 64.45B | 67.42B | 66.99B | 70.84B | 34.86B | 37.00B |
| Total Liabilities | 117.21B | 121.39B | 124.90B | 137.21B | 101.29B | 104.01B |
| Stockholders Equity | 90.10B | 86.48B | 88.20B | 89.01B | 95.66B | 77.20B |
Cash Flow | ||||||
| Free Cash Flow | 9.48B | 9.08B | 9.84B | 4.79B | 26.03B | 29.87B |
| Operating Cash Flow | 11.98B | 11.71B | 12.74B | 8.70B | 29.27B | 32.58B |
| Investing Cash Flow | -3.84B | -1.35B | 2.65B | -32.28B | -15.78B | -22.55B |
| Financing Cash Flow | -7.93B | -10.30B | -17.14B | 26.07B | -14.83B | -9.82B |
Pfizer Technical Analysis
Negative
27.56
Price Trends
25.65
Negative
26.23
Negative
25.26
Negative
Market Momentum
-0.51
Positive
32.86
Neutral
19.41
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PFE, the sentiment is Negative. The current price of 27.56 is above the 20-day moving average (MA) of 25.18, above the 50-day MA of 25.65, and above the 200-day MA of 25.26, indicating a bearish trend. The MACD of -0.51 indicates Positive momentum. The RSI at 32.86 is Neutral, neither overbought nor oversold. The STOCH value of 19.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PFE.
Pfizer Risk Analysis
Pfizer disclosed 26 risk factors in its most recent earnings report. Pfizer reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Pfizer Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $309.64B | 35.23 | 17.93% | 3.12% | 2.70% | -48.28% | |
71 Outperform | $611.38B | 29.29 | 26.26% | 2.50% | 7.87% | -3.56% | |
71 Outperform | $282.14B | 22.12 | 31.54% | 2.87% | 5.60% | 9.68% | |
66 Neutral | $195.01B | 24.95 | 89.41% | 3.00% | 9.94% | 31.14% | |
64 Neutral | $136.10B | 18.23 | 8.37% | 6.65% | 1.36% | -5.39% | |
61 Neutral | $443.57B | 123.10 | 68.01% | 2.87% | 9.50% | -13.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
PFE
Pfizer
23.88
0.21
0.90%
AMGN
Amgen
361.33
73.14
25.38%
JNJ
Johnson & Johnson
253.98
101.34
66.39%
MRK
Merck & Company
125.37
45.65
57.26%
NVS
Novartis
154.14
32.71
26.94%
ABBV
AbbVie
251.06
66.33
35.91%
Pfizer Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Pfizer Reaffirms 2026 Outlook Amid CFO Transition
Positive
Jun 18, 2026
Following its June 18, 2026 announcement of a Chief Financial Officer transition, Pfizer reaffirmed the full-year 2026 financial guidance it first issued on December 16, 2025 and reiterated on May 5, 2026. The company continues to project 2026 rev...
Executive/Board ChangesShareholder Meetings
Pfizer Shareholders Reaffirm Leadership, Governance at 2026 Meeting
Positive
Apr 27, 2026
Pfizer shareholders held their Annual Meeting on April 23, 2026, where they re-elected the full slate of board nominees, including Chief Executive Albert Bourla and other incumbent directors, for terms lasting until the next annual meeting. Invest...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.